⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31078723 | 0.98 | F2 (0.95) | — | |
| Trifluoroacetic Acid SCHEMBL5656425 | 0.88 | F2 (0.77) | — | |
| SCHEMBL6181512 | 0.84 | F2 (0.71) | — | |
| SCHEMBL18649308 | 0.83 | — | — | |
| SCHEMBL9144815 | 0.82 | F2 (0.70) | — | |
| SCHEMBL76028 | 0.80 | — | — | |
| SCHEMBL3745752 | 0.80 | — | — | |
| SCHEMBL1770739 | 0.80 | — | — | |
| SCHEMBL17088064 | 0.80 | — | — | |
| SCHEMBL15525171 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112500403-B | Preparation method of rivaroxaban | 南京法恩化学有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-112500403-A | Preparation method of rivaroxaban | 南京法恩化学有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-104788444-B | The preparation method of razaxaban | 浙江天顺生物科技有限公司 | 2018-11-06 | — | — | CN | claimed |
| CN-104910141-B | A kind of preparation method of the chloro- N- of Rivaroxaban intermediate 5- (2- oxiranylmethyl radicals) -2- thenoyl amines | 浙江天顺生物科技有限公司 | 2018-11-02 | — | — | CN | claimed |
| CN-107089974-A | A kind of preparation method of razaxaban | 辅仁药业集团有限公司 | 2017-08-25 | — | — | CN | claimed |
| EP-2661433-B1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2017-08-16 | — | — | EP | claimed |
| EP-2771327-B1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | claimed |
| US-9403808-B2 | Pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | claimed |
| CN-104910141-A | Preparation method for Rivaroxaban intermediate 5-chloro-N-(2-oxiranylmethyl)-2-thiophene methanamide | ZHEJIANG TIANSHUN BIOTECHNOLOGY CO LTD | 2015-09-16 | — | — | CN | claimed |
| CN-104788444-A | Preparation method of rivaroxaban | ZHEJIANG TIANSHUN BIOTECHNOLOGY CO LTD | 2015-07-22 | — | — | CN | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | claimed |
| JP-2003508353-A | — | — | 2003-03-04 | — | — | JP | claimed |
| EP-1051176-A4 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARM PROD INC (US) | 2002-06-12 | — | — | EP | claimed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | claimed |
| JP-2002501024-A | — | — | 2002-01-15 | — | — | JP | claimed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | claimed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | claimed |
| EP-1051176-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2000-11-15 | — | — | EP | claimed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | claimed |